$GSK Company News Mylan in second round bid for Glaxo

New Post Public Reply Private Reply Replies (0) Message Board

Aug 23, 2014 at 12:21 PM

$GSK Company News

Mylan in second round bid for Glaxo portfolio: WSJ 2:39 p.m. Aug. 20, 2014 - MarketWatch.com
Glaxo chief faces increasing pressure: WSJ 6:29 p.m. Aug. 11, 2014 - MarketWatch.com
Super-Moon illusion or buy the dips on this stock market? 7:52 a.m. Aug. 11, 2014 - Barbara Kollmeyer
China’s anti-corruption drive: Is it reform in disguise? 1:26 a.m. Aug. 11, 2014 - Craig Stephen
Hungry for yield? Gobble up European stocks, says Goldman 10:43 a.m. Aug. 5, 2014 - Carla Mozee
FTSE 100 slumps for third day as miners, banks slump 12:12 p.m. Aug. 1, 2014 - Sara Sjolin
FTSE 100 erases gain after soft U.S. home sales data 12:07 p.m. July 28, 2014 - Sara Sjolin
Biogen rallies on earnings; Juniper slumps 10% 1:25 p.m. July 23, 2014 - Sue Chang
Glaxo slides in London after earnings warning 12:02 p.m. July 23, 2014 - Carla Mozee
GlaxoSmithKline lowers full-year profit outlook 7:48 a.m. July 23, 2014 - MarketWatch.com
U.K. growth data to reignite BOE rate chatter 5:08 a.m. July 22, 2014 - blogs.marketwatch.com
Emerging markets lift Novartis profit by 1.6% 1:39 a.m. July 17, 2014 - MarketWatch.com
Novartis lays out plan to overhaul business 3:14 a.m. June 18, 2014 - MarketWatch.com
GlaxoSmithKline reaches $105 million settlement with 44 states 3:19 p.m. June 4, 2014 - Russ Britt
Merck, Sanofi, Glaxo explore shedding older drugs 5:43 p.m. June 3, 2014 - MarketWatch.com
GlaxoSmithKline says U.K. fraud office is probing its commercial work 4:07 p.m. May 27, 2014 - Russ Britt
GlaxoSmithKline says U.K. fraud office probing firm 3:27 p.m. May 27, 2014 - Russ Britt
Vodafone pulls FTSE 100 from 14-year high 12:18 p.m. May 15, 2014 - Sara Sjolin
Glaxo's ex-China chief accused of bribery 1:20 a.m. May 14, 2014 - MarketWatch.com
Glaxo profit slides by almost a third 10:07 a.m. April 30, 2014 - MarketWatch.com

FDA approves single-pill regimen HIV med 3:32 p.m. Aug. 22, 2014 - Seeking Alpha
GlaxoSmithKline's (GSK) Arnuity Ellipta Approved by FDA - Analyst Blog 5:05 p.m. Aug. 21, 2014 - Zacks.com
3 Dividend Kings From The U.K. I Love To Buy 3:01 p.m. Aug. 21, 2014 - GuruFocus.com
Theravance Biopharma: Neglected Spinoff Targeting A Huge Underserved Market 9:32 a.m. Aug. 21, 2014 - Seeking Alpha
Novartis to Invest $35M in Gamida Cell for 15% Equity - Analyst Blog 6:13 p.m. Aug. 20, 2014 - Zacks.com
GSK expands fluticasone furoate label into asthma 3:49 p.m. Aug. 20, 2014 - Seeking Alpha
GlaxoSmithKline: The Bad Isn't All That Bad 3:39 p.m. Aug. 20, 2014 - Seeking Alpha
Why Mylan (MYL) Stock Is Advancing Today 3:01 p.m. Aug. 20, 2014 - TheStreet.com
UPDATE: GlaxoSmithKline Receives FDA Approval For Arnuity Ellipta In US For Treatment Of Asthma 2:36 p.m. Aug. 20, 2014 - benzinga.com
Hottest Healthcare Stocks Now – THOR GSK ESRX CNC 1:45 p.m. Aug. 20, 2014 - InvestorPlace.com
Eurozone Recovery Stalls in Q2: 3 Stocks to Sell Now - Analyst Blog 9:59 a.m. Aug. 20, 2014 - Zacks.com
Pernix acquires U.S. rights to Treximet 9:03 a.m. Aug. 20, 2014 - Seeking Alpha
Yes, Call it a Comeback: Amicus Fabry Drug Posts Big Study Win 6:01 a.m. Aug. 20, 2014 - TheStreet.com
GlaxoSmithKline: To Buy Or Not To Buy? 12:27 p.m. Aug. 19, 2014 - Seeking Alpha
Kindred 30.33% Upside Paced Healthcare August Dividend Dogs 9:18 p.m. Aug. 18, 2014 - Seeking Alpha
Sinopharm, Biostar, Lilly Rise on Medical Modernization in China 2:11 p.m. Aug. 18, 2014 - TheStreet.com
Guru Stocks at 52-Week Lows: PFE, GSK, VOD, EC, MFG 10:54 a.m. Aug. 18, 2014 - GuruFocus.com
Why GlaxoSmithKline Is A Tempting Buy 5:10 p.m. Aug. 14, 2014 - Seeking Alpha
Major Portfolio Changes for Warren Buffett and Berkshire Hathaway 4:40 p.m. Aug. 14, 2014 - 247WallSt.com
Ebola vaccine trials are a top priority for medical authorities 1:20 p.m. Aug. 14, 2014 - Seeking Alpha

ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection 3:46 p.m. Aug. 22, 2014 - PR Newswire - PRF
Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 11:00 a.m. Aug. 21, 2014 - PR Newswire - PRF
Pharma Stocks Review -- Eli Lilly, Zogenix, GlaxoSmithKline, Novo Nordisk, and Valeant Pharma Intl. 9:20 a.m. Aug. 21, 2014 - PR Newswire - PRF
GSK receives FDA approval for Arnuity™ Ellipta® (fluticasone furoate) in the US for the treatment of asthma 3:33 p.m. Aug. 20, 2014 - PR Newswire - PRF
Pernix Therapeutics Closes Acquisition of Treximet. Raises $220m Senior Notes. Issues Updated 2014 Guidance. 8:02 a.m. Aug. 20, 2014 - BusinessWire - BZX
POZEN Announces U.S. Rights For TREXIMET® Have Been Acquired by Pernix Therapeutics 8:00 a.m. Aug. 20, 2014 - BusinessWire - BZX
North American Pharma-Biotech Sector to Wrap Up Construction on 157 Projects Worth $1.3 Billion in Third-Quarter 2014, an Industrial Info News Alert 6:15 a.m. Aug. 20, 2014 - Marketwire
Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 1:19 p.m. Aug. 19, 2014 - PR Newswire - PRF
Sanford-Burnham Appoints Perry Nisen as Chief Executive Officer 1:00 p.m. Aug. 19, 2014 - Marketwire
Drug Approvals & Updates, Licensing Agreements, and Upcoming Conferences - Research Reports on Tekmira, MannKind, Eli Lilly, GSK and Cigna 8:30 a.m. Aug. 14, 2014 - PR Newswire - PRF
Inotek Pharmaceuticals Names David P. Southwell as President and Chief Executive Officer 9:01 a.m. Aug. 13, 2014 - BusinessWire - BZX
Potential Payoffs Spur Big Board Biotech Action 3:03 p.m. Aug. 12, 2014 - ACCESSWIRE
Thrasos Appoints Gaétan Gravel andJoseph Zakrzewski to Board of Directors 9:01 a.m. Aug. 12, 2014 - BusinessWire - BZX
Spasticity Global Clinical Trials Review, H2, 2014 4:42 p.m. Aug. 11, 2014 - PR Newswire - PRF
Spastic Cerebral Palsy Global Clinical Trials Review, H2, 2014 4:39 p.m. Aug. 11, 2014 - PR Newswire - PRF
Sears Holdings Names Alasdair James As Kmart's President And Chief Member Officer 2:47 p.m. Aug. 11, 2014 - PR Newswire - PRF
Sponsor And CRO Finalists Announced For Annual Society For Clinical Research Sites Eagle Award 12:08 p.m. Aug. 11, 2014 - PR Newswire - PRF
Dynavax Reports Second Quarter 2014 Financial Results and Safety and Pharmacodynamic Results for Asthma and Lupus Drug Candidates 6:01 a.m. Aug. 7, 2014 - Marketwire
New Joint Ventures, Course Launches, Study Results, Earnings Performance, and Approvals - Research Reports on Johnson Controls, Intuitive Surgical, GlaxoSmithKline, Community Health and Vertex 8:50 a.m. Aug. 6, 2014 - PR Newswire - PRF
GSK's COPD.com Relaunch Promotes Understanding and Dialogue about COPD 9:00 a.m. Aug. 5, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Meteor Education Bolsters CTE Reach with AET Labs Buy

Meteor's Move: AET Labs Picked Up in CTE Plays You see, Meteor Education ain't sitting on its hands, that's for sure. They're out here hoarding strategic pieces like it's a chess match, snatching up AET Labs to bolster their already sturdy CTE playbook. No financial details spilled, but hell, that’s par for the course. This move plants them even more firmly in New...

GNSS Simulator Market: $425M by 2031, Key Insight

GNSS Simulator Market: Gadgets Meet Growth A market that's been quietly bubbling away on the back burner is about to boil over: The GNSS Simulator Market, pegged at a neat $424.6 million by 2031. Yeah, it might be niche, but those in the know can't get enough of these satellite-signal replicators. Why GNSS Simulators are Crushing It There's a bunch of reasons why GNSS...

Ensign Group Faces Class Action Amid Stock Plummet

Ensign Group's Recent Troubles Unraveled Let's set the scene: Ensign Group, once riding high at over $170 a share, finds itself knee-deep in allegations that'll make any investor squirm. Now, we're not just talking about a typical market fluctuation here – this is a real smackdown with an 8.2% drop, all thanks to some damning accusations. A Closer Look at Allegations...

Endava Facing Securities Fraud Suit; Stocks Down 24%

Endava Hits Rough Patch with Legal Battle Brewing So here we are, watching Endava plc struggle through legal quagmires and tumbling stock prices. Come September 21, 2026, news hit the street: Endava's CFO, Mark Thurston, found himself on administrative leave due to an investigation surrounding some shaky accounting practices. The Audit Committee raised a red flag, and...

Xi Jinping's Vision for China's Financial Evolution

Xi's Blueprint for Financial Strength Xi Jinping isn't just whistling Dixie when it comes to reshaping China's financial landscape. His vision is about more than pushing paper; it's about embedding honesty, prudence, and traditional values into the very DNA of China's financial sector. When he talks about enhancing both hard and soft power, he’s thinking wider than...

D-Wave Faces Securities Fraud Class Action: Details Inside

D-Wave Quantum Inc. in Hot Water Well folks, looks like D-Wave Quantum Inc. (NASDAQ: QBTS) is knee-deep in a securities fraud class action lawsuit. This ain't just another day in the quantum computing trenches. We've got Kessler Topaz Meltzer & Check, LLP, a big player in securities litigation, rallying the troops here—a clear sign that this case is packing some hefty...

Cars24, Alba Cars Merge to Supercharge UAE Ventures

An Unlikely Pair Turbocharging the Industry Sometimes, melding two distinct styles creates something extraordinary—like peanut butter and jelly or, in this case, Cars24 and Alba Cars. You get a combination of global tech platform savvy with premium retail chops. It’s kind of like blending the future with the tried-and-true past in automotive retail. Growing Pains or...

BOC Group Sustains Leadership in Enterprise Architecture

BOC Group's Continued Dominance It's not every day you see a company like BOC Group sticking to the Leader spot in Gartner's Magic Quadrant for six straight years. Anyone entrenched in enterprise architecture can recognize what a feat that is. Their tool, ADOIT, isn't just riding the AI trend—it’s steering it. It's like they've got this knack for fusing technology...

Q-Ball Intelligence Launches Predictive Powerhouse

Breaking Out in the Predictive AI Scene Q-Ball Intelligence doesn't just stroll onto the AI stage; they bulldoze in, backed by a beefy research legacy starting way back in 2007. Now, after 19 years marinating in the depths of predictive research—and putting some serious cash where their AI mouth is—they've officially launched as the new big thing in predictive...

Differentia Bio's AI: Transforming Drug Development Dynamics

The Future of Drug Development: AI's New Role When it comes to pharmaceutical R&D, Some outfits are playing pin the tail on the donkey, but Differentia Bio over here is sharpening the pin with some futuristic gadgetry. Yep, they're jazzing up the game with AI-powered digital twins, building lifelike disease environments that predict therapeutic outcomes with precision...